Immunotherapy advances in head and neck cancer care: implications for prescribers
Journal of Prescribing Practice · 02.04.2026 · 8 (4) · 144-147
DOI: 10.12968/jprp.2026.0040 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Prescribing Practice, erschienen am 02.04.2026. Verfasst von Aysha Mendes. Die Arbeit nennt 8 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Aysha Mendes discusses how pembrolizumab is reshaping the treatment of locally advanced head and neck cancer by introducing immunotherapy into treatment and care, requiring prescribers to recognise and support co-ordinated, patient-centred management across settings
Zitieren
APA
Mendes, A. (2026). Immunotherapy advances in head and neck cancer care: implications for prescribers. Journal of Prescribing Practice, 8(4), 144-147. https://doi.org/10.12968/jprp.2026.0040
Vancouver
Mendes A. Immunotherapy advances in head and neck cancer care: implications for prescribers. Journal of Prescribing Practice. 2026;8(4):144-147. doi:10.12968/jprp.2026.0040
BibTeX
@article{Mendes2026,
author = {Mendes, Aysha},
title = {Immunotherapy advances in head and neck cancer care: implications for prescribers},
journal = {Journal of Prescribing Practice},
year = {2026},
volume = {8},
number = {4},
pages = {144--147},
doi = {10.12968/jprp.2026.0040}
}
EUVIMED